Literature DB >> 25359683

MicroRNA profile of tumorigenic cells during carcinogenesis of lung adenocarcinoma.

Zhen-guo Zhao1, Jun-yu Jin, An-mei Zhang, Lu-ping Zhang, Xin-xin Wang, Jian-guo Sun, Zheng-tang Chen.   

Abstract

To obtain microRNA (miRNA) profile and clarify their biological function in tumorigenic Sca-1(+) CD34(+) cells during carcinogenesis of lung adenocarcinoma. After intranasal infection with recombinant Adeno-Cre viruses (AdV-Cre), lung adenocarcinoma was identified pathologically in Lox-stop-lox Kras (LSL-Kras) G12D mice. Sca-1(+) CD34(+) cells were sorted by flow cytometry and tested for tumor-initiating ability, self-renewal and tumorigenicity. MiRNA profiles were obtained using microarray and further confirmed by real-time RT-PCR (qRT-PCR). MiRNA functions were predicted bioinformatically, and miR-294 function was verified to explore its role in tumor migration and invasion. Lung adenocarcinoma was induced in LSL-Kras G12D mice within 30 days. In vivo, the tumorigenicity of Sca-1(+) CD34(+) cells was 25 times stronger than Sca-1(-) CD34(-) cells. During tumorigenesis of lung adenocarcinoma, the expression of 145 miRNAs in Sca-1(+) CD34(+) cells increased and 72 miRNAs decreased (P < 0.01). Four successively up-regulated miRNAs (miR-15a*, miR-203, miR-294 and miR-295*) and three successively down-regulated ones (miR-19b, miR-483 and miR-615-5p) were identified. Among them, miR-294 could constitutively bind to 3'-UTR of matrix metalloproteinase 3 (MMP3), and down-regulate MMP3 protein expression. MiR-294 also significantly inhibited migration and invasion of Lewis lung cancer cells. MiRNAs are characteristically expressed in tumor-initiating Sca-1(+) CD34(+) cells of lung adenocarcinoma, and may play important roles during the carcinogenesis of lung adenocarcinoma.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  CARCINOGENESIS; LUNG ADENOCARCINOMA; TUMORIGENIC CELLS; miRNAs

Mesh:

Substances:

Year:  2015        PMID: 25359683     DOI: 10.1002/jcb.24999

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  8 in total

1.  Role of miR-101 in pheochromocytoma patients with SDHD mutation.

Authors:  Ligeng Zong; Lizhen Meng; Ruhui Shi
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

2.  Reproducibility of histopathological findings in experimental pathology of the mouse: a sorry tail.

Authors:  Jerrold M Ward; Paul N Schofield; John P Sundberg
Journal:  Lab Anim (NY)       Date:  2017-03-22       Impact factor: 12.625

3.  MicroRNA-144 regulates proliferation, invasion, and apoptosis of cells in malignant solitary pulmonary nodule via zinc finger E-box-binding homeobox 1.

Authors:  Guizhi Zhang; Huaijie An; Xiangqun Fang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 4.  The roles of microRNAs related with progression and metastasis in human cancers.

Authors:  Hai-Ting Liu; Peng Gao
Journal:  Tumour Biol       Date:  2016-10-06

5.  Pleiotropic functions of the tumor- and metastasis-suppressing matrix metalloproteinase-8 in mammary cancer in MMTV-PyMT transgenic mice.

Authors:  Julie Decock; Wouter Hendrickx; Sally Thirkettle; Ana Gutiérrez-Fernández; Stephen D Robinson; Dylan R Edwards
Journal:  Breast Cancer Res       Date:  2015-03-14       Impact factor: 6.466

6.  MicroRNA-155-3p promotes hepatocellular carcinoma formation by suppressing FBXW7 expression.

Authors:  Bo Tang; Biao Lei; Guangying Qi; Xingsi Liang; Fang Tang; Shengguang Yuan; Zhenran Wang; Shuiping Yu; Songqing He
Journal:  J Exp Clin Cancer Res       Date:  2016-06-16

Review 7.  Role of miR-483 in digestive tract cancers: from basic research to clinical value.

Authors:  Wei Zhou; Wanli Yang; Jiaojiao Ma; Hongwei Zhang; Zeng Li; Lei Zhang; Jinqiang Liu; Zhenyu Han; Hu Wang; Liu Hong
Journal:  J Cancer       Date:  2018-01-01       Impact factor: 4.207

8.  miR-1290 promotes lung adenocarcinoma cell proliferation and invasion by targeting SOCS4.

Authors:  Xuelian Xiao; Daheng Yang; Xue Gong; Dongping Mo; Shiyang Pan; Jian Xu
Journal:  Oncotarget       Date:  2018-01-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.